Mitigating Ocular Surface Disease in Patients With Glaucoma

Learn about the critical need to evaluate glaucoma patients for ocular surface disease and the proactive measures to ensure optimal visual outcomes.

1

More than half of glaucoma patients experience chronic ocular surface disease (OSD) due to eyedrop therapy affecting tear film stability.
2

Evaluating glaucoma patients for OSD is essential to detect symptoms that may not be reported, impacting their adherence to glaucoma medications.
3

Non-drop therapies, such as intracameral implants and selective laser trabeculoplasty, can reduce eyedrop burden and prevent OSD.
4

Minimally invasive glaucoma surgery (MIGS) offers a viable treatment option for glaucoma patients, minimizing OSD associated with traditional therapies.
5

Effective OSD treatment in glaucoma patients requires initial screening and may include preservative-free medications and advanced therapies like cryopreserved amniotic membrane.

1